Inovio Pharmaceuticals Inc
F:GBM
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Inovio Pharmaceuticals Inc
F:GBM
|
US |
|
P
|
ProMIS Neurosciences Inc
F:23J
|
CA |
|
LVMH Moet Hennessy Louis Vuitton SE
MIL:1MC
|
FR |
|
BRP Inc
TSX:DOO
|
CA |
|
Shanghai Electric Group Co Ltd
OTC:SIELF
|
CN |
|
Hoth Therapeutics Inc
NASDAQ:HOTH
|
US |
|
Nexpoint Real Estate Finance Inc
NYSE:NREF
|
US |
|
Ferrari NV
MIL:RACE
|
IT |
|
H
|
Heritage Global Inc
F:LGC
|
US |
|
C
|
China Mobile Ltd
DUS:CTM
|
CN |
|
A
|
aTyr Pharma Inc
SWB:471A
|
US |
|
Iovance Biotherapeutics Inc
NASDAQ:IOVA
|
US |
|
S
|
Schneider Electric SE
XMUN:SND
|
FR |
|
Abb Ltd
F:ABJA
|
CH |
Wall St Price Targets
GBM Price Targets Summary
Inovio Pharmaceuticals Inc
According to Wall Street analysts, the average 1-year price target for
GBM is 5.972 EUR with a low forecast of 3.1 EUR and a high forecast of 10.744 EUR.
Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What you see on other sites is mostly sourced from sell-side analysts.
What is GBM's stock price target?
Price Target
5.972
EUR
According to Wall Street analysts, the average 1-year price target for
GBM is 5.972 EUR with a low forecast of 3.1 EUR and a high forecast of 10.744 EUR.
What is the Revenue forecast for Inovio Pharmaceuticals Inc?
Projected CAGR
163%
Over the last 13 years, the compound annual growth rate for Revenue has been -27%. The projected CAGR for the next 8 years is 163%.